TIDMODX

Omega Diagnostics Group PLC

14 November 2022

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

Partnership agreement with Nutrigenomics Software Provider

Creating detailed lifestyle and dietary guidance reports from genetic data

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has signed heads of terms with regards to a partnership agreement (the "Agreement") with a leading nutrigenomics software provider to develop and commercialise a bespoke DNA report for Omega.

The report will be a unique and proprietary software tool which will expand the Company's product portfolio in line with its stated strategy to broaden its menu of tests. By u nderstanding the relationship between nutrients, diet, and gene expression, nutrigenomics allows healthcare professionals to understand genetic strengths and weaknesses, making specific recommendations that help achieve better health outcomes for patients.

The parties will collaborate with a view to improving the awareness and understanding in the market of nutrigenomic testing, including the publication of educational materials and scientific studies. The report, which is intended to be utilised by healthcare professionals and their patients, will be designed to meet Omega's specific requirements while incorporating the current data and structure of the software provider's existing reports.

This Agreement follows on from the microbiome testing partnership which was announced on 26 October 2022 and, once completed, will conclude the Company's initial product range expansion as previously set out in the Company's strategic plan.

Jag Grewal, CEO of Omega Diagnostics said: "We are pleased to have signed this second strategic partnership, this time with a leading nutrigenomics software provider, which will give the Company a broader and complementary range of tests to help manage gut health and improve patient outcomes for those living with chronic diseases. Our focus remains on commercial and service development within the sector, as we seek to grow revenues and further consolidate our established market leading position, thus enabling the Board's vision of delivering personalised nutrition for better health."

Contacts:

 
 Omega Diagnostics Group PLC                                            www.omegadx.com 
 Jag Grewal, Chief Executive Officer                                    via Walbrook PR 
 Chris Lea, Chief Financial Officer 
 
 finnCap Ltd                                                         Tel: 020 7220 0500 
 Geoff Nash/Edward Whiley/George Dollemore (Corporate 
  Finance) 
 Alice Lane/Charlotte Sutcliffe 
  (ECM) 
 
 Walbrook PR Limited                         Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus / Sam Allen / Lianne                 Mob: 07980 541 893 / 07502 558 258 / 
  Applegarth                                                              07584 391 303

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

www.omegadx.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFLFLDLRLLLIF

(END) Dow Jones Newswires

November 14, 2022 02:00 ET (07:00 GMT)

Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Omega Diagnostics Charts.
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Omega Diagnostics Charts.